Risperidone (Perseris, Risperdal, Uzedy) — 2026 Medicare Part D coverage
risperidone — sold as Perseris, Risperdal, Uzedy: 36 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover risperidone?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| risperiDONE 0.25 MG Disintegrating Oral Tablet generic · RxCUI 645037 | 328 (100%) | 4 | 45 | 61 | 246 |
| risperiDONE 0.25 MG Oral Tablet generic · RxCUI 312828 | 328 (100%) | 2 | 0 | 0 | 153 |
| risperiDONE 0.5 MG Disintegrating Oral Tablet generic · RxCUI 403825 | 328 (100%) | 4 | 45 | 61 | 246 |
| risperiDONE 0.5 MG Oral Tablet generic · RxCUI 312829 | 328 (100%) | 2 | 0 | 0 | 153 |
| risperiDONE 1 MG Disintegrating Oral Tablet generic · RxCUI 401953 | 328 (100%) | 4 | 45 | 61 | 246 |
| risperiDONE 1 MG Oral Tablet generic · RxCUI 312830 | 328 (100%) | 2 | 0 | 0 | 153 |
| risperiDONE 1 MG in 1 mL Oral Solution generic · RxCUI 199387 | 328 (100%) | 2 | 44 | 0 | 201 |
| risperiDONE 12.5 MG Extended Release Injection generic · RxCUI 706822 | 328 (100%) | 4 | 26 | 3 | 271 |
| risperiDONE 2 MG Disintegrating Oral Tablet generic · RxCUI 401954 | 328 (100%) | 4 | 45 | 61 | 246 |
| risperiDONE 2 MG Oral Tablet generic · RxCUI 312831 | 328 (100%) | 2 | 0 | 0 | 153 |
| risperiDONE 25 MG Extended Release Injection generic · RxCUI 402010 | 328 (100%) | 4 | 26 | 3 | 271 |
| risperiDONE 3 MG Disintegrating Oral Tablet generic · RxCUI 616698 | 328 (100%) | 4 | 45 | 61 | 243 |
| risperiDONE 3 MG Oral Tablet generic · RxCUI 312832 | 328 (100%) | 2 | 0 | 0 | 153 |
| risperiDONE 37.5 MG Extended Release Injection generic · RxCUI 402011 | 328 (100%) | 5 | 26 | 3 | 269 |
| risperiDONE 4 MG Disintegrating Oral Tablet generic · RxCUI 616705 | 328 (100%) | 4 | 45 | 61 | 243 |
| risperiDONE 4 MG Oral Tablet generic · RxCUI 314211 | 328 (100%) | 2 | 0 | 0 | 151 |
| risperiDONE 50 MG Extended Release Injection generic · RxCUI 402012 | 328 (100%) | 5 | 26 | 3 | 268 |
| PERSERIS 120 MG in 0.8 mL Prefilled Syringe brand · RxCUI 2055672 | 173 (53%) | 5 | 23 | 0 | 144 |
| PERSERIS 90 MG in 0.6 mL Prefilled Syringe brand · RxCUI 2055676 | 173 (53%) | 5 | 23 | 0 | 144 |
| UZEDY 100 MG in 0.28 ML Prefilled Syringe brand · RxCUI 2636039 | 89 (27%) | 5 | 19 | 4 | 76 |
| UZEDY 125 MG in 0.35 ML Prefilled Syringe brand · RxCUI 2636042 | 89 (27%) | 5 | 19 | 4 | 76 |
| UZEDY 150 MG in 0.42 ML Prefilled Syringe brand · RxCUI 2636044 | 89 (27%) | 5 | 19 | 4 | 76 |
| UZEDY 200 MG in 0.56 ML Prefilled Syringe brand · RxCUI 2636046 | 89 (27%) | 5 | 19 | 4 | 76 |
| UZEDY 250 MG in 0.7 ML Prefilled Syringe brand · RxCUI 2636048 | 89 (27%) | 5 | 19 | 4 | 76 |
| UZEDY 50 MG in 0.14 ML Prefilled Syringe brand · RxCUI 2636050 | 89 (27%) | 5 | 19 | 4 | 76 |
| UZEDY 75 MG in 0.21 ML Prefilled Syringe brand · RxCUI 2636052 | 89 (27%) | 5 | 19 | 4 | 76 |
| RisperDAL CONSTA 12.5 MG Injection brand · RxCUI 706825 | 17 (5%) | 4 | 1 | 2 | 15 |
| RisperDAL CONSTA 25 MG Injection brand · RxCUI 706831 | 17 (5%) | 4 | 1 | 2 | 15 |
| RisperDAL CONSTA 37.5 MG Injection brand · RxCUI 706827 | 17 (5%) | 5 | 1 | 2 | 13 |
| RisperDAL CONSTA 50 MG Injection brand · RxCUI 706829 | 17 (5%) | 5 | 1 | 2 | 12 |
| RisperDAL 0.5 MG Oral Tablet brand · RxCUI 262222 | 1 (0%) | 1 | 1 | 0 | 1 |
| RisperDAL 1 MG Oral Tablet brand · RxCUI 104781 | 1 (0%) | 1 | 1 | 0 | 1 |
| RisperDAL 1 MG in 1 mL Oral Solution brand · RxCUI 211489 | 1 (0%) | 1 | 1 | 0 | 1 |
| RisperDAL 2 MG Oral Tablet brand · RxCUI 104782 | 1 (0%) | 1 | 1 | 0 | 1 |
| RisperDAL 3 MG Oral Tablet brand · RxCUI 104783 | 1 (0%) | 1 | 1 | 0 | 1 |
| RisperDAL 4 MG Oral Tablet brand · RxCUI 104784 | 1 (0%) | 1 | 1 | 0 | 1 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.